Watch TRVI. Know when insiders buy.
One email the day a filing lands. Free.
TRVI
Trevi Therapeutics, Inc.
15.21
+0.20 +1.33%
USD · close Sep 17
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
63
WATCH · shorts 63
Insiders, 90 days
−$596K
net selling · 0 buys, 4 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.2BP/E —DIV YIELD —FCF YIELD -2.44%REV TTM —NET INCOME −$51.1MNET CASH —52W 8.15 – 19.50SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$20.5M | −$17.8M | — | -0.11 | −$17.4M | $124K | −$17.6M | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$14.9M | −$13.2M | — | -0.09 | −$16.7M | $102K | −$16.8M | May 5 |
| Q4 2025 · Dec 31derived | — | — | — | −$10.2M | −$8.3M | — | -0.06 | −$7.6M | $0 | −$7.6M | Mar 17 |
| Q3 2025 · Sep 30 | — | — | — | −$13.9M | −$11.8M | — | -0.08 | −$10.9M | $12K | −$10.9M | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$13.7M | −$12.3M | — | -0.09 | −$10.1M | — | — | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$11.5M | −$10.3M | — | -0.09 | −$13.5M | — | — | May 5 |
| Q4 2024 · Dec 31derived | — | — | — | −$12.2M | −$11.4M | — | -0.11 | −$9.6M | $7K | −$9.6M | Mar 17 |
| Q3 2024 · Sep 30 | — | — | — | −$14.1M | −$13.2M | — | -0.13 | −$9.6M | $0 | −$9.6M | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$13.3M | −$12.4M | — | -0.12 | −$8.7M | — | — | Aug 7 |
| Q1 2024 · Mar 31 | — | — | — | −$11.9M | −$10.9M | — | -0.11 | −$10.5M | — | — | May 8 |
| Q4 2023 · Dec 31derived | — | — | — | −$8.9M | −$7.8M | — | -0.08 | −$6.4M | $22K | −$6.4M | Mar 18 |
| Q3 2023 · Sep 30 | — | — | — | −$9M | −$7.7M | — | -0.08 | −$7.3M | $18K | −$7.3M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$49.3M | −$42.8M | — | -0.32 | −$42.1M | $12K | −$42.1M | — | — |
| FY2024 · to Dec 31 | — | — | −$51.5M | −$47.9M | — | -0.47 | −$38.3M | $35K | −$38.3M | — | — |
| FY2023 · to Dec 31 | — | — | −$33.9M | −$29.1M | — | -0.29 | −$31.7M | $137K | −$31.8M | — | — |
| FY2022 · to Dec 31 | — | — | −$29.9M | −$29.2M | — | -0.45 | −$28.2M | $159K | −$28.3M | — | — |
| FY2021 · to Dec 31 | — | — | −$32.5M | −$33.9M | — | -1.49 | −$28.9M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$32.5M | −$32.8M | — | -1.81 | −$29M | $32K | −$29M | — | — |
Every number comes from Trevi Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.